These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30594050)

  • 1. Anti-aggregation effect on platelets of Indiplon a hypnotic sedative non-benzodiazepine drug.
    Burgos CF; Sanchéz C; Sepúlveda C; Fuentes E; Palomo I; Alarcón M
    Biomed Pharmacother; 2019 Mar; 111():378-385. PubMed ID: 30594050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenosine A
    Fuentes E; Fuentes M; Caballero J; Palomo I; Hinz S; El-Tayeb A; Müller CE
    Platelets; 2018 May; 29(3):292-300. PubMed ID: 28504052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood Platelet Adenosine Receptors as Potential Targets for Anti-Platelet Therapy.
    Wolska N; Rozalski M
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31684173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective mechanisms of adenosine 5'-monophosphate in platelet activation and thrombus formation.
    Fuentes E; Badimon L; Caballero J; Padró T; Vilahur G; Alarcón M; Pérez P; Palomo I
    Thromb Haemost; 2014 Mar; 111(3):491-507. PubMed ID: 24306059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeine alters A2A adenosine receptors and their function in human platelets.
    Varani K; Portaluppi F; Merighi S; Ongini E; Belardinelli L; Borea PA
    Circulation; 1999 May; 99(19):2499-502. PubMed ID: 10330379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors.
    Petroski RE; Pomeroy JE; Das R; Bowman H; Yang W; Chen AP; Foster AC
    J Pharmacol Exp Ther; 2006 Apr; 317(1):369-77. PubMed ID: 16399882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of adenosine derivatives to carrier proteins may reduce their antiplatelet activity.
    Wzorek J; Bednarek R; Watala C; Boncler M
    Biochem Pharmacol; 2020 Apr; 174():113827. PubMed ID: 31987853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indiplon: the development of a new hypnotic.
    Neubauer DN
    Expert Opin Investig Drugs; 2005 Oct; 14(10):1269-76. PubMed ID: 16185169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GABAA receptor pharmacology of fluorinated derivatives of the novel sedative-hypnotic pyrazolopyrimidine indiplon.
    Wegner F; Deuther-Conrad W; Scheunemann M; Brust P; Fischer S; Hiller A; Diekers M; Strecker K; Wohlfarth K; Allgaier C; Steinbach J; Hoepping A
    Eur J Pharmacol; 2008 Feb; 580(1-2):1-11. PubMed ID: 18035350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indiplon: a nonbenzodiazepine sedative-hypnotic for the treatment of insomnia.
    Marrs JC
    Ann Pharmacother; 2008 Jul; 42(7):1070-9. PubMed ID: 18594049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
    Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
    Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.
    Carter LP; Griffiths RR; Suess PE; Casada JH; Wallace CL; Roache JD
    J Pharmacol Exp Ther; 2007 Aug; 322(2):749-59. PubMed ID: 17502431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new role for the A2b adenosine receptor in regulating platelet function.
    Yang D; Chen H; Koupenova M; Carroll SH; Eliades A; Freedman JE; Toselli P; Ravid K
    J Thromb Haemost; 2010 Apr; 8(4):817-27. PubMed ID: 20102488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic.
    Foster AC; Pelleymounter MA; Cullen MJ; Lewis D; Joppa M; Chen TK; Bozigian HP; Gross RS; Gogas KR
    J Pharmacol Exp Ther; 2004 Nov; 311(2):547-59. PubMed ID: 15256538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
    Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
    Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
    Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
    Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of H2-receptor antagonists on platelet function in vitro.
    Nakamura K; Kariyazono H; Shinkawa T; Yamaguchi T; Yamashita T; Ayukawa O; Moriyama Y; Yotsumoto G; Toyohira H; Taira A; Yamada K
    Hum Exp Toxicol; 1999 Aug; 18(8):487-92. PubMed ID: 10462360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation.
    Kuriyama S; Kashiwagi H; Yuhki K; Kojima F; Yamada T; Fujino T; Hara A; Takayama K; Maruyama T; Yoshida A; Narumiya S; Ushikubi F
    Thromb Haemost; 2010 Oct; 104(4):796-803. PubMed ID: 20664890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the interaction of indiplon, a novel pyrazolopyrimidine sedative-hypnotic, with the GABAA receptor.
    Sullivan SK; Petroski RE; Verge G; Gross RS; Foster AC; Grigoriadis DE
    J Pharmacol Exp Ther; 2004 Nov; 311(2):537-46. PubMed ID: 15256540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.